Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI)

Journal of Hepatology

Volumn 44, Issue 3, 2006, Pages 484-490

  Maynard, Marianne ^a   Pradat, Pierre ^a   Bailly, François ^a   Rozier, Frédéric ^a   Nemoz, Chantal ^b   Si Ahmed, Si Nafa ^c   Adeleine, Patrice ^b   Trépo, Christian ^a  

^a HÔTEL DIEU   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

Author keywords

Amantadine; Clinical trial; Hepatitis C; Treatment; Triple therapy

Indexed keywords

AMANTADINE; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EVALUATION; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; AMANTADINE; ANTIVIRAL AGENTS; BIOPSY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 32444436365     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.11.038     Document Type: Article

References (32)

1. M. Duncan, and Z. Younossi Treatment options for nonresponders and relapsers to initial therapy for hepatitis C Clev Clin J Med 70 2003 S21 S26
2. F.Y. Aoki, and D.S. Sitar Clinical pharmacokinetics of amantadine hydrochloride Clin Pharmacokinet 14 1988 35 51
3. S.D. Griffin, L.P. Beales, D.S. Clarke, O. Worsfold, S.D. Evans, and J. Jaeger The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine Fed Eur Biol Soc Lett 535 2003 34 38
4. S.D. Griffin, R. Harvey, D.S. Clarke, W.S. Barclay, M. Harris, and D.J. Rowlands A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria J Gen Virol 85 2004 451 461
5. D. Pavlovic, D.C. Neville, O. Argaud, B. Blumberg, R.A. Dwek, and W.B. Fischer The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives Proc Natl Acad Sci USA 100 2003 6104 6108
6. T. Kanda, O. Yokosuka, F. Imazeki, K. Fujiwara, H. Saisho, and K. Nagao Amantadine has direct inhibitory effects against hepatitis A internal ribosomal entry site-mediated translation Hepatology 40 2004 286A
7. S. Brillanti, F. Levantesi, L. Masi, M. Foli, and L. Bolondi Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C Hepatology 32 2000 630 634
8. P.J. Thuluvath, H. Pande, and J. Maygers Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin Dig Dis Sci 48 2003 594 597
9. G. Teuber, M. Pascu, T. Berg, M. Lafrenz, J. Pausch, and F. Kullmann Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C J Hepatol 39 2003 606 613
10. L.E. Adinolfi, R. Utili, A. Tonziello, and G. Ruggiero Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial Gut 52 2003 701 705
11. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR cooperative study group. Hepatology 1994;20:15-20.
12. M.L. Shiffman Retreatment of patients with chronic hepatitis C Hepatology 36 2002 S128 S134
13. M.L. Shiffman, A.M. Di Bisceglie, K.L. Lindsay, C. Morishima, E.C. Wright, and G.T. Everson Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015 1023 [discussion 1947]
14. A. Mangia, G. Leandro, B. Helbling, E.L. Renner, M. Tabone, and L. Sidoli Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials J Hepatol 40 2004 478 483
15. P. Deltenre, J. Henrion, V. Canva, S. Dharancy, F. Texier, and A. Louvet Evaluation of amantadine in chronic hepatitis C: a meta-analysis J Hepatol 41 2004 462 473
16. T. Bizollon, M. Adham, P. Pradat, M. Chevallier, C. Ducerf, and J. Baulieux Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C Transplantation 79 2005 325 329
17. F. Hasan, J. Al-Khaldi, H. Asker, M. Al-Ajmi, S. Owayed, and R. Varghese Peginterferon alpha-2b plus ribavirin with or without amantidine for the treatment of non-responders to standard interferon and ribavirin Antivir Ther 9 2004 499 503
18. A. Zaman, M.B. Fennerty, and E.B. Keeffe Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C Aliment Pharmacol Ther 18 2003 661 670
19. The IDEAL study: individualized dosing efficacy vs. flat dosing to assess optimal pegylated inteferon therapy. http://www.idealstudy.com
20. F. Torre, R. Giusto, A. Grasso, R. Brizzolara, N. Campo, and N. Sinelli Clearance kinetics of hepatitis C virus under different antiviral therapies J Med Virol 64 2001 455 459
21. G. Lake-Bakaar, L. Ruffini, and P. Kuzmic Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon Dig Dis Sci 48 2003 126 139
22. S. Caronia, M.F. Bassendine, R. Barry, P. Mills, N.V. Naoumov, and R. Fox Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study J Hepatol 35 2001 512 516
23. M. Tabone, C. Laudi, B. Delmastro, A. Biglino, M. Andreoni, and F. Chieppa Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients J Hepatol 35 2001 517 521
24. A. Craxi, and O. Lo Lacono Amantadine for chronic hepatitis c: a magic bullet or yet another dead duck? J Hepatol 35 2001 527 530
25. H. Suzuki, R. Saito, H. Masuda, H. Oshitani, M. Sato, and I. Sato Emergence of amantadine-resistant influenza A viruses: epidemiological study J Infect Chemother 9 2003 195 200
26. R. Saito, T. Sakai, I. Sato, Y. Sano, H. Oshitani, and M. Sato Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2 J Clin Microbiol 41 2003 2164 2165
27. K. Shiraishi, K. Mitamura, Y. Sakai-Tagawa, H. Goto, N. Sugaya, and Y. Kawaoka High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza J Infect Dis 188 2003 57 61
28. I. Vuillermoz, E. Khattab, E. Sablon, I. Ottevaere, D. Durantel, and C. Vieux Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy J Med Virol 74 2004 41 53
29. J. Martin, S. Navas, M. Fernandez, M. Rico, M. Pardo, and J.A. Quiroga In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients Antiviral Res 42 1999 59 70
30. J.P. Smith, T.R. Riley III, S. Bingaman, and D.T. Mauger Amantadine therapy for chronic hepatitis C: a dose escalation study Am J Gastroenterol 99 2004 1099 1104
31. E. Formann, W. Jessner, R. Hubmann, C. Datz, P. Munda-Steindl, and A. Klingler Effect of amantadine on quality of life and fatigue in patients with chronic hepatitis C participating in a prospective, double blind, placebo-controlled, randomized trial of treatment with pegylated interferon alfa2a/ribavirin Hepatology 40 2004 338A
32. J.K. Lim, D. Wooten, R. Siegel, and R.C. Cheung Amantadine in treatment of chronic hepatitis C virus infection? J Viral Hepat 12 2005 445 455